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The development of animal model to evaluate the toxicological action of compounds used as 
pharmaceutical drugs is desired. The model described in this work is based on the capability of drugs 
to alter the bioavailability of radiopharmaceuticals (radiobiocomplexes) labeled with technetium-99 m 
(99mTc). There are evidences that the bioavailability or the pharmacokinetic of radiobiocomplexes can be 
modified by some factors, as drugs, due to their toxicological action in specific organs. Vincristine is a 
natural product that has been utilized in oncology. The vincristine effect on the bioavailability of the 
radiobiocomplexes 99mTc-methylenediphosphonic acid (99mTc-MDP) and 99mTc-pyrophosphate (99mTc-
PYP) in Balb/c female mice was evaluated. The fragments of kidney were processed to light microscopy 
and transmission electron microscopy. The aim of this work was to study at structural and 
ultrastructural levels the alterations caused by vincristine in organs. One hour after the last dose of 
vincristine, 99mTc-PYP or 99mTc-MDP was injected, the animals were sacrificed and the percentage of 
radioactivity (%ATI) was determined in the isolated organs. Concerning 99mTc-PYP, the %ATI (i) 
decreased in spleen, thymus, lymph nodes (inguinal and mesentheric), kidney, lung, liver, pancreas, 
stomach, heart and brain and (ii) increased in bone and thyroid.  Concerning 99mTc-MDP, the %ATI (iii) 
decreased in spleen, thymus, lymph nodes (inguinal and mesentheric), kidney, liver, pancreas, 
stomach, heart, brain, bone, ovary and uterus. In conclusion, the toxic effect of vincristine in 
determined organs could be responsible for the alteration of the uptake of the studied 
radiobiocomplexes.    
 





Although the great relevance of nuclear medicine is well 
characterized, some authors have reported that other 
factors, in addition to the disease, can interfere in the 





The lack of knowledge of these factors is undesirable, 
and the consequences are (i) the possibility of misdiagno-
sis (misleading information that can either mask or mimic 
certain disease symptoms) and/or (ii) the repetition of the 
examination with an increase in radiation dose to the 
patient (Hladik et al., 1987; Sampson, 1999). Some 
authors have reported   that various synthetic drugs 
(medications) are capable of altering the bioavailability of 
different radiobiocomplexes (Hladik et al., 1987; 
Hesslewood and Leung, 1994; Sampson, 1999). 
Moreover, other authors have suggested that medicinal 
plants (natural drugs) can be also associated with the 
drug interaction with radiobiocomplexes. Santos-Filho et 
al. (2004) have reported that Mentha crispa altered the 
bioavailability of the Na99mTcO4 and there is an increase 
of the radioactivity in the thyroid.  Moreno et al. (2004) 
have verified that the Ginkgo biloba alters the bioavaila-
bility of Na99mTcO4 in rats.  Santos-Filho and Bernardo 
Filho (2005) have demonstrated that Hypericum 
perforatum decreases the bioavailability of the Na99mTcO4 
in the bone, muscle and thyroid and increases the 
bioavailability in pancreas. Passos et al. (2002) have also 
demonstrated that dietary conditions can also interfere 
with the bioavailability of radiobiocomplexes. The type of 
the food seems to contribute to unexpected bioavailability 
of radiobiocomplex (Capriles et al., 2002; Diré et al., 
2003). 
   The radiobiocomplexes have been in use for many 
years for diagnosis and therapy of a wide variety of 
diseases (Saha, 2004). Since a therapeutic drug or a 
natural product (Hung et al., 1996; Oliveira et al., 1997; 
Vidal et al., 1998) can also modify (i) the nature of the 
99mTc-radiobiocomplex, (ii) the biochemical milieu to 
which the radiobiocomplex is exposed or (iii) its capability 
to bind to blood elements, an unexpected behavior of the 
radiobiocomplex may be observed in patients under drug 
therapy. It has been reported that vincristine interferes 
with the adrenal cortex imaging when this clinical evalua-
tion is carried out using 131I-iodomethylnorcholesterol and 
75Se-selenomethylnorcholesterol. It is observed an in-
crease in the renal retention due to nephrotoxicity of this 
chemotherapeutic drug (Sampson, 1993; Hesslewood 
and Leung, 1994; Owunwanne, 1995; Saha, 2004).  
Vincristine is a chemotherapeutic drug used in several 
protocols in oncology. Evidence exists that the combi-
nation of cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) was associated with toxicity as 
nausea or vomiting, alopecia, peripheral neurologic 
toxicity, and constipatin (Zinzani et al., 2004). Vincristine 
is used together with interferon, cyclophosphamide, bleo-
mycin, imiquimod, becaplermin, and laser therapy in the 
treatment of infantile hemangiomas (Pandey et al., 2008). 
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in common with other drugs such as colchicine and 
podophyllotoxin, block cells in mitosis (Chabner et al., 
1996). The biological activities of this drug can be 
explained by its ability to bind specifically to tubulin and to 
block the ability of the protein to polymerize into micro-
tubules. Through disruption of the microtubules of the 
mitotic apparatus, cell division is arrested in metaphase. 
In addition to their key role in the formation of mitotic 
spindles, microtubules are involved in other cellular 
functions such as movement, phagocytosis, and axonal 
transport. Side effects of the vinca alkaloids, such as their 
neurotoxicity, may be due to disruption of these functions 
(McQuairrie, 1987; Chabner et al., 1996).  
This drug has a broad spectrum of anti-tumor activity 
and it is used on the treatment of childish leukemia, solid 
tumor, Hodgkin disease and other lymphomas 
(Anderson, 1981; Mareel and De Mets, 1984; Salloum 
and Schubert, 1996).   Such multi-drug-resistant tumor 
cells display cross-resistance to vinca alkaloids, 
epipodophyllotoxins, anthracyclines, dactinomycin, and 
colchicine. Chromosomal abnormalities consistent with 
gene amplification have been observed in resistant cells 
in culture, and the cells contain markedly increased the 
levels of the P-glycoprotein. A membrane efflux pump 
that transports drugs from the cells Ca2+-channel 
blockers, such as verapamil, can reverse the resistance 
of this type. Other membrane transporters may mediate 
multi-drug resistant, still other forms of resistance to vinca 
alkaloids involve mutations in tubulin gene that prevent 
the effective binding of the inhibitors to their target 
(Chabner et al., 1996). 
   The introduction of the short half-life technetium-99 m 
(99mTc) in 1960 paved the way for convenient method of 
radiolabelling (Saha, 2004). 99mTc is the isotope most 
commonly used in nuclear medicine, because of its 
nuclear characteristics: emission of gamma radiation of 
low energy (140keV), short half-life (6 h), absence of beta 
emission, 100% of decay by isomeric transition to 99Tc. 
Labeled molecules with 99mTc are used for visualization of 
many organs (Saha, 2004; Moraes et al., 2005). 
   Bone metastases are the commonest contributor to 
morbidity in cancer patients, especially in those with 
breast and prostate cancer (Coleman, 1997; Vinã, 2005). 
Metastatic bone dissemination gives rise to pain, with 
pain being the most frequent clinical manifestation from 
bone metastases (Vinã, 2005).  Biphosphonates have 
become an integral tool in the management of malignant 
bone disease, but they had not demonstrated clinical 
benefit in men with prostate cancer until recently (Saad et 
al., 2004).  Bone scintigraphy is one the most frequently 
performed of all radionuclide procedures. Radionuclide 
bone imaging is quick, relatively inexpensive, widely 
available, and is invaluable in the diagnostic evaluation of 
numerous pathologic conditions. The procedure is perfor- 
med with technetium-99 m-labeled diphosphonates (Love 
et al., 2003).   
   It is well established that phosphorous compounds 
have affinity for hydroxyapatite  crystals.  Following  intra- 




venous injection, the 99mTc-phosphorus-radiobiocomplex 
is bound to bone surface probably as a result of 
adsorption on to the hydroxyapatite crystal (Owunwanne, 
1995). 99mTc-phosphorus-radiobiocomplex also accumu-
lates in infarcted myocardium owing to adsorption onto 
amorphous calcium phosphate or by complexation with 
denatured native proteins and other macromolecules. 
The major pathway of elimination of 99mTc-phosphorus-
radiobiocomplex is through the kidney.    
The main uses of these radiobiocomplexes are to the 
localization of primary bone tumors, metastatic tumors 
and metabolic bone diseases (Sampson, 1993; 
Owunwanne, 1995). These radiobiocomplexes are 
utilized for bone scanning. 99mTc-PYP has been widely 
used in the detection of myocardial infarcts. A variety of 
drug interactions has been documented which affect the 
bioavailability of the radiobiocomplex and hence could 
influence the diagnosis of diseases (Hesslewood and 
Leung, 1994). 
With the aim to develop an animal model to study the 
toxicological effect of drugs and as a patient under 
chemotherapeutic treatment can be submitted to a 
nuclear medicine procedure, we  decided to evaluate the 
effect of vincristine on the bioavailability of  two radio-
biocomplexes used for bone evaluations, the 99mTc-MDP 





The experiments with the use of animals were conducted in 
accordance with the ethical protocol established for the Instituto de 
Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio 
de Janeiro, and with the Guide to the Care and Use of Experimental 
Animals (1984). Vincristine (Oncovin, Eli Lilly do Brasil Ltda, Brazil) 
(0.03 mg, 0.3 ml) was administered by ocular plexus via into female 
isogenic Balb/c mice (n=15), in three doses with a total interval of 
96 h. For the studies in the transmission electron microscopy the 
fragments of kidney were fixed in 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer (pH 7.2), added in 0.25% tannic acid. The 
postfixation was in 1% OsO4, 0.8% potassium ferricyanide 
(K3Fe(CN)6)  and 5 mM calcium cloride (CaCl2) in 0.1 M cacodylate 
buffer. The tissues were dehydrated in acetone and embedded in 
epon. For light microscopy semithin sections were stained in 
toluidine blue and observed in optical microscope (Olympus BH2-
RFCA, Japan). For transmission electron microscopy (TEM) ultra-
thin sections were stained in uranyl acetate and lead citrate and 
observed in transmission electron microscope (EM 906 Zeiss). One 
hour after the last dose, 0.3 ml of 99mTc-MDP or 99mTc-PYP (7.4 
MBq) was injected by the same via. In the control group (n=15), 
vincristine was not administered. To prepare the 99mTc-MDP or 
99mTc-PYP, 99mTc, as sodium pertechnetate, recently milked from a 
99Mo/99mTc generator (Instituto de Pesquisas Energéticas e 
Nucleares, Brazil) was added to a kit of PYP or MDP (Laboratório 
de Radiofarmácia, INCa, Brazil). The radiochemical control was 
performed by ascendent chromatography, using paper Whatman no 
1 and 0.9% NaCl solution and acetone as mobile phases. The 
labeling efficiency was > 95% and the percentage of free 
pertechnetate was < 5%. After 0.5 h the animals were rapidly 
sacrificed. The various organs were isolated: pancreas, thyroid, 
brain, thymus, ovary, uterus, spleen, kidney, heart, stomach, lung, 
liver, bone and lymph nodes (inguinal and mesentheric), and the 





counter NaI(Tl) (Automatic Gamma Counter, 1272 Clinigamma, 
LKB, Wallac, Finland). The percentages of radioactivity (% ATI) in 
the organs were calculated dividing the activity in each organ by the 
total activity administered. The percentage of radioactivity in each 
organ was compared between the two groups, control and the 
treated with vincristine. Statistical analysis was performed by 





The effect of vincristine on the uptake of the 99mTc-MDP 
in isolated organs from treated and no treated animals is 
shown in Tables 1 and 2. The results concerning the 
99mTc-PYP are shown in Tables 3, 4 and 5. Table 1 
shows the uptake (%ATI) of 99mTc-MDP in different 
organs and the analysis of the results reveals a decrease 
of the uptake in uterus, ovary, spleen, thymus, lymph 
nodes (inguinal and mesentheric), kidney, liver, pan-
creas, stomach, heart, brain and bone. Table 2 shows the 
uptake (%ATI) of 99mTc-MDP in various organs and the 
analysis of the results reveals no significant reduction of 
the uptake in lung and thyroid. Table 3 shows that the 
uptake (%ATI) of 99mTc-PYP was decreased in spleen, 
thymus, lymph nodes (inguinal and mesentheric), kidney, 
lung, liver, pancreas, stomach, heart and brain. Table 4 
shows that the %ATI of 99mTc-PYP was increased in bone 
and thyroid. Table 5 shows that the radioactivity of 99mTc-
PYP was not altered in uterus and ovary. 
The results in the light microscope observations did not 
demonstrate alterations in both control and treated 
animals (Figure 1). The electron micrograph (Figure 2) of 
control animal kidney shows glomerular capillaries 
presenting fenestration of the endothelial cells. The 
fenestrae of the capillaries are bridged by diaphragms. 
The pedicels are shown around the basal membrane 
involving the capillary. The electron micrograph of animal 
treated kidney (Figure 3) displays a glomerular capillary 
where identified fenestrae of irregular outline, a thicken-





The use of protocols with vincristine is widely used in 
oncology. Many biological effects of vincristine have 
already reported (Chabner et al., 1996; McQuarrie, 
1987). Interestingly, there is no data in the literature 
establishing animal model to study the biological effect of 
pharmaceuticals. Here, we evaluated the action of 
chemotherapeutic drugs in the interaction with radio-
pharmaceuticals using Balb/c female mice (Mattos et al., 
2001; Gomes et al., 2002a; Gomes et al., 2002b). 
Besides, an unexpected pattern of radiopharmaceutical 
distribution provokes a flurry of inquiries regarding the 
quality of the administered agent. But, the alterations in 
biodistribution may be related to the chemotherapeutic 
drug interaction (Mattos et al., 2000; Mattos et al., 2001; 
Gomes   et   al.,  2002a).  Any   chemical  agent  or  other




Table 1. Effect of vincristine on the bioavailability of technetium-99m-




Vincristine was administered by ocular plexus via into female mice Balb/c into mice (treated 
group). The control group did not receive vincristine. After 96hr, 99mTc-MDP was also 
injected in both groups of animals. The animals were sacrificed, the organs isolated and the 
activities (%ATI) determined in each organ. The values are mean ± standard deviation 
(n=15). The results were compared with the control group, without vincristine, and statistical 




Table 2. Effect of vincristine on the biodistribution of technetium-




Lung 0.1777 ± 0.0239 0.1770 ± 0.0287 
Thyroid 0.0367 ± 0.0039 0.0360 ± 0.0066 
 
Vincristine was administered by ocular plexus via into female mice 
Balb/c into mice (treated group). The control group did not receive 
vincristine. After 96hr, 99mTc-MDP was also injected in both groups of 
animals. The animals were sacrificed, the organs isolated and the 
activities (%ATI) determined in each organ. The values are mean ± 
standard deviation (n=15). The results were compared with the control 
group, without vincristine, and statistical anallysis were performed 




influence, including a drug, which alters the nature of the 
biochemical milieu to which tracer is exposed, may result 
in unexpected behavior of the radiopharmaceutical (Hung 
et al., 1996; Sampson, 1993). 
Vincristine has been used as a component of many 
chemotherapeutic regimens because of its elative lack of 
hematologic toxicity. Its mechanism of action is by 
interfering with microtubule formation and exerts immuno-
supressive activity (Mareel and De Mets, 1984; 
McQuarrie, 1987; Chabner et al., 1996; Salloum and 
Schubert, 1996). This immunosupressive activity could 
explain the decrease of the 99mTc-PYP and 99mTc-MDP in 
thymus, spleen and lymph nodes (inguinal and 
mesentheric). This alteration was related to 99mTc-MDP 
(Mattos et al., 1999); it was observed an alteration in 
uptake in thymus and spleen (Gomes et al., 1998; Britto 
et al., 1998; Mattos et al., 2000). 
The alterations, in the treated animals with vincristine, 
of the uptake of 99mTc-PYP and 99mTc-MDP in kidneys 
can be due to the capability of this natural compound to 
produce hyponatremia with abnormal water retention due 
(probably) to the nonsmotic release of antidiuretic 
hormome (Chabner et al., 1996) or due to the described 
nephrotoxicity of vincristine (Hesslewood and Leung, 
1994). This alteration was related to 99mTc-MDP, 99mTc-
DTPA and 99mTc-DMSA (Gomes et al., 1998; Britto et al., 
1998; Mattos et al., 1999; Mattos et al., 2001). The 
results in the light microscope observations did not 
demonstrate alterations in both control and treated 
animals. The electron micrograph of control animal kid-
ney shows glomerular capillaries presenting fenestration 
of the endothelial cells. The fenestrae of the capillaries 
are bridged by diaphragms. The pedicels are shown 
around the basal membrane involving the capillary. The 
electron micrograph of animal treated kidney displays a 
glomerular capillary where identified fenestrae of irregular 
outline, a thickening basal membrane and pedicels is 
absent. 
This chemotherapeutic agent is metabolized in liver 
and the conjugates and metabolites are excreted in the 
bile. In patients with hepatic dysfunctions (bilirubin 
greater than 3 mg/dl), a 75% reduction in the vincristine 
dose is advisable (Anderson, 1981; Chabner et al., 
1996). The necessity of this dose adjustment of this vinca  
 
                  Organ 
%ATI 
        Control                Treated 
Uterus 0.0379 ± 0.0039 0.0104 ± 0.0028    p<0.05 
Ovary 0.0179 ± 0.0014 0.0045 ± 0.0011    p<0.05 
Spleen 0.0406 ± 0.0013 0.0193 ± 0.0011    p<0.05 
Thymus 0.0216 ± 0.0038 0.0083 ± 0.0019    p<0.05 
Lymph node inguinal 0.1055 ± 0.0074 0.0062 ± 0.0017    p<0.05 
Lymph node mesentheric 0.0528 ± 0.0153 0.0058 ± 0.0008    p<0.05 
Kidney 0.4540 ± 0.0252 0.1723 ± 0.0217    p<0.05 
Liver 0.2616 ± 0.0184 0.0880 ± 0.0050    p<0.05 
Pancreas 0.0225 ± 0.0048 0.0087 ± 0.0017    p<0.05  
Stomach 0.1531 ± 0.0142 0.0606 ± 0.0115    p<0.05 
Heart 0.1141 ± 0.0146 0.0385 ± 0.0095    p<0.05 
Brain 0.2163 ± 0.0311 0.0271 ± 0.0053    p<0.05 
Bone 1.1132 ± 0.0584 0.3882 ± 0.0803    p<0.05 










            Control                 Treated 
Spleen 0.3549 ± 0.0463     0.0426 ± 0.0064  p<0.05 
Thymus 0.0976 ± 0.0197     0.0095 ± 0.0021  p<0.05 
Lymph node inguinal 0.1014 ± 0.0202     0.0184 ± 0.0018  p<0.05 
Lymph node mesentheric 0.0324 ± 0.0070     0.0135 ± 0.0018   p<0.05 
Kidney 2.6711 ± 0.2475     0.7030 ± 0.1339   p<0.05 
Lung 0.3407 ± 0.0242     0.1871 ± 0.0092  p<0.05 
Liver 2.9122 ± 0.4501     1.1738 ± 0.0824  p<0.05 
Pancreas 0.0622 ± 0.0056     0.0124 ± 0.0028  p<0.05 
Stomach 0.3069 ± 0.0617     0.1325 ± 0.0135  p<0.05 
Heart 0.8078 ± 0.1098     0.1138 ± 0.0093  p<0.05 
Brain 0.4077 ± 0.0863     0.0717 ± 0.0112  p<0.05 
 
Vincristine was administered by ocular plexus via into female mice Balb/c into mice (treated 
group). The control group did not receive vincristine. After 96hr, 99mTc-PYP was also injected 
in both groups of animals. The animals were sacrificed, the organs isolated and the activities 
(%ATI) determined in each organ. The values are mean ± standard deviation (n=15). The 
results were compared with the control group, without vincristine, and statistical anallysis were 




Table 4. Effect of vincristine on the biodistribution of technetium-





       Control                  Treated 
Bone 0.0717 ± 0.0081    0.7872 ± 0.1170   p<0.05 
Thyroid 0.0141 ± 0.0028    0.0821 ± 0.0213   p<0.05 
 
Vincristine was administered by ocular plexus via into female mice 
Balb/c into mice (treated group). The control group did not receive 
vincristine. After 96hr, 99mTc-PYP was also injected in both groups of 
animals. The animals were sacrificed, the organs isolated and the 
activities (%ATI) determined in each organ. The values are mean ± 
standard deviation (n=15). The results were compared with the control 
group, without vincristine, and statistical anallysis were performed 




alkaloid could be due to the possible toxic effect of 
vincristine in the liver and this fact could justify the 
decrease in the uptake of the 99mTc-PYP and 99mTc-MDP 
in this organ. This alteration was related to 99mTc-MDP, 
99mTc-PYP, 99mTc-DTPA and 99mTc-DMSA (Mattos et al., 
1999; Mattos et al., 2001; Gomes et al., 2002a).  Rutin 
increased the uptake of 99mTcO4Na in liver (Bernardo et 
al., 2004). Rutin is a flavonoid used in conventional and 
traditional medicine. This substance presents many bio-
logical effects, like anti-inflammatory and antispasmodic 
(Botsaris and Machado, 1999) and has been suggested 
many pharmacological activities, including myocardial 
protection and vasodilator (Janbaz et al., 2002). 
Side effects of the vinca alkaloids, such as their 
neurotoxicity, have predictable cumulative effects. Numb-
ness and tingling of the extremities, loss  of  deep  tendon 
 
Table 5. Effect of vincristine on the biodistribution of technetium-






Uterus 0.0810 ± 0.0086 0.0811 ± 0.0099 
Ovary 0.0294 ± 0.0033 0.0292 ± 0.0029 
 
Vincristine was administered by ocular plexus via into female mice 
Balb/c into mice (treated group). The control group did not receive 
vincristine. After 96hr, 99mTc-PYP was also injected in both groups of 
animals. The animals were sacrificed, the organs isolated and the 
activities (%ATI) determined in each organ. The values are mean ± 
standard deviation (n=15). The results were compared with the control 
group, without vincristine, and statistical anallysis were performed 
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Figure 1. Photomicrographies (x 400) of kidney without alteration 








Figure 2. Electron micrograph of control animal kidney that did not 
receive the chemotherapeutic drug. The glomerular capillaries (C) 
presenting the fenestrae (small arrows) are observed. The basal 
membrane (big arrows) surround the capillaries. The pedicels 




reflexes, and weakness of distal limb musculature consti-
tute the most common and earliest signs. Inadvertent 
intrathecal vincristine administration produces devastat-
ing and invariably fatal central neurotoxicity, with seizures 
and irreversible coma (Anderson, 1981; McQuaire, 1987; 
Chabner et al., 1996). These neurological effects could 
justify the alteration in the fixation of the 99mTc-PYP and 
99mTc-MDP in brain that is improved by the vincristine 
treatment. 
As bone marrow suppression is the most frequent 
complications in the protocols with vincristine (Anderson, 
1981) this could alter the fixation of the 99mTc-PYP and 
99mTc-MDP in bone. This alteration was observed to 
chemotherapic mitomycin-C to 99mTc-PYP and to 99mTc-
PHY (Gomes et al., 2002a; Gomes et al., 2002b). 
Cigarette smoke is a complex mixture of chemicals 
containing more than 4000 different constituents. Some 
of the compounds identified include pyridine alkaloids, 
such as nicotine. It was reported that this drug altered the 
biodistribution of Na99mTcO4 in bone, kidney, lung, spleen 
stomach, testis and thyroid (Valença et al., 2005). 
Ischemic cardiac toxicity and gastrointestinal symtoms 
have been observed during vincristine therapy 
(McQuaire, 1987; Chabner et al., 1996). These 
alterations probably could explain the decreased of the 
uptake of the studied radiobiocomplexes observed in 
heart, stomach and pancreas. These results were 
observed in 99mTc-MDP and 99mTc-DMSA (Mattos et al., 
1999; Mattos et al., 2001). 
In conclusion, the results could be explained by the 
metabolization and/or therapeutic and immunosupressive 
action of vincristine. Moreover, as vincristine alters the 
uptake of both 99mTc-MDP and 99mTc-PYP in the  bone,  it  






Figure 3.  Electron micrograph of kidney of animal treated with 
the drug. The glomerular capillary is observed containing a red 
blood cell (H). Fenestrae (arrow) of irregular outline, a basal 
lamina thickened (asterisks) and absence of pedicels are 




could be necessary to be careful in the interpretation of 
the examination of patients under this treatment, although 
our results were obtained with animals. Furthermore, the 
analysis of the results show that is possible to employ 
this model to evaluate the toxic effect of pharmaceuticals 
used by human beings. The effect of this chemothe-
rapeutic drug on the bioavailability with other 99mTc-
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